NAC Attack: Phase III Multicenter Randomized Parallel Double Masked Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients with Retinitis Pigmentosa
Enrolling By Invitation
18-99 years
All
Phase
3
20 participants needed
1 Location
Brief description of study
Currently, this study is recruiting among patients at Penn Medicine. It is not accepting non-Penn Medicine patient participants.
The objective of the study will be to evaluate the efficacy and safety of oral N-acetylcysteine (NAC) in patients with retinitis pigmentosa (RP). The study is a multi-center, randomized, placebo-controlled study where adult patients diagnosed with RP will be asked to take 1800mg NAC bid or a placebo. Patients will be followed for 45 months with a series of clinic visits, tele-visits and phone calls, and safety and efficacy will be assessed using tests to measure visual function and structure.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: retinitis pigmentosa
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 853552
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
